Skip to main content

Table 1 Summary of participant characteristics

From: Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer

Clinical characteristic

Total n = 14

Age (years)

 

Median

64

Range

52–75

Sex, n (%)

 

Female

6 (43)

Male

8 (57)

Ethnicity, n (%)

 

White (British, Irish, other)

14 (100)

Black (African, British, Carribean)

0 (0)

Asian (Asian, British)

0 (0)

other

0 (0)

Smoking status, n (%)

 

Never smoker

0 (0)

Ex-smoker

10 (72)

Smoker

4 (28)

Unknown

0 (0)

ECOG PS, n (%)

 

0

3 (21)

1

11 (79)

Histopathology, n (%)

 

NSCLC-adenocarcinoma

10 (72)

NSCLC-squamous cell carcinoma

2 (14)

NSCLC-NOS

2 (14)

PD-L1 TPS, n (%)

 

< 1%

5 (36)

1–49%

1 (7)

≥ 50%

8 (57)

Metastatic status, n (%)

 

M0 or Mx

2 (14)

M1a

5 (36)

M1b

4 (29)

M1c

3 (21)

  1. Metastatic status is according to baseline diagnostic TNM staging according to 8th Edition of TNM in Lung Cancer. See Additional file 1: Table S1 for individual participant demographics including TNM staging, disease sites and administered radioactivity
  2. ECOG Eastern Cooperative Oncology Group Performance score, NOS not otherwise specified, NSCLC non-small cell lung cancer, PD-L1 programmed death-ligand 1, TPS tumour proportion score